Causaly, an AI start­up help­ing with pre­clin­i­cal dis­cov­ery, nabs $60M from VCs and for­mer J&J chief Alex Gorsky

The AI hype isn’t let­ting up: An­oth­er start­up in the pre­clin­i­cal dis­cov­ery world has reeled in a fresh $60 mil­lion, in­clud­ing in­vest­ment from John­son & John­son’s for­mer chair and CEO Alex Gorsky.

Lon­don and San Fran­cis­co com­pa­ny Causaly dis­closed its Se­ries B Thurs­day morn­ing, say­ing it now serves 12 of the top 20 phar­ma com­pa­nies. Gilead, No­vo Nordisk, Re­gen­eron and the FDA are among its cus­tomers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER